Buy Crypto
Markets
Spot
FuturesBTC
Earn
Event Center
Rewards Hub
More
100%+ PoR
BIIB

Biogen Inc. (BIIB)

NASDAQ
$251.37
+$0.63
(+0.25%)
Previous Close: ⁦$250.79⁩
Market Closed

Last updated: ⁦2026-11-19 02:28:40⁩. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.

Summary

Biogen Inc. (BIIB) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $251.37, with a market capitalization of $37.20B and a P/E ratio of 106.68. Over the past 52 weeks, its price has ranged from $160.36 to $261.00. This page covers its latest market performance, valuation, price trends and company information.

Key Market Data

$37.20B

$247.78

$254.29

$245.65

$250.79

903.77K

1.09M

106.68

$261.00

$160.36

--

2026-09-30

Biogen Inc. (BIIB) Latest Closing Stock Price

Biogen Inc. (BIIB) last closed at $251.37 as of 2026-11-19 00:58:00, up 0.25% ($0.63) from the previous close of $250.79.

During the latest regular trading session, BIIB traded between $245.65 and $254.29, with a volume of 903.77K shares. The closing price was near the upper end and near the upper end of its 52-week range.

Biogen Inc. (BIIB) 7-Day Stock Price Change

Over the past seven days, Biogen Inc. (BIIB) moved from $254.87 to $251.37, representing a decline of 1.37% ($3.50).

The stock traded between $245.65 and $261.00 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.

The average daily volume was 946.28 thousand shares, down versus the previous seven-day period, indicating lower trading activity.

BIIB 52-Week Price Position

Position in Range: 90.4%

52W Low$160.36
52W High$261.00

BIIB is currently trading at $251.37, placing it 90.4% of the way from its 52-week low of $160.36 to its 52-week high of $261.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.

What is Biogen Inc. (BIIB)?

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Biogen Inc. Information

Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
7,500
CEO
Christopher A. Viehbacher
Founded
1978
Exchange
NASDAQ
Company Website

BIIB News

Latest news related to Biogen Inc. and BIIB stock.

  • Massive

    New Three-Year Real-World LEQEMBI® Data Presented at CTAD 2026

    Eisai and Biogen announced three-year real-world findings from the LEADER study of 560 patients showing LEQEMBI reduced progression to moderate/severe Alzheimer's disease by 76% compared to natural history controls. The analysis demonstrated 81% of patients remained stable or improved, 77% achieved amyloid-negative status, and subcutaneous maintenance therapy showed favorable safety profiles with no ARIA events reported.

    Read Full Article
  • Benzinga

    Biogen Reports Two-Year Data Showing Diranersen Slows Early Alzheimer's Decline

    Biogen reports two-year Phase 2 CELIA data showing diranersen slows clinical decline and cuts tau biomarkers in early Alzheimer's disease.

    Read Full Article
  • Benzinga

    Biogen Says New Data From The Phase 2 CELIA Study Shows Increasing Clinical Benefit Of Diranersen; Diranersen Slowed Clinical Decline By 38% On CDR-SB At Two Years With The 60 Mg Twice-Yearly Regimen, Corresponding To A 1.09-Point Treatment Difference

    Read Full Article
  • Massive

    Biogen: 3 Key Takeaways for Long-Term Investors

    Biogen reported strong Q3 2026 results with core pharmaceutical revenue of $2 billion and 18% year-over-year growth. The Apellis acquisition added $1 billion in annual run-rate revenue and achieved ahead-of-schedule cost synergies, enabling growth independent of pipeline success. High-dose SPINRAZA conversion exceeded targets with 70% of patients submitting start forms, while late-stage clinical trials in immunology and kidney disease offer multiyear growth potential.

    Read Full Article
  • Massive

    Biotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex and Moderna Post Strong 2026 Results as Billion-Dollar Deals Reshape a Market Headed for USD 6.34 Trillion by 2035

    The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.

    Read Full Article

Ways to Trade BIIB at MEXC

BIIB MEXC RealStocks

Own real BIIB shares through MEXC's regulated brokerage partner.


Suitable for long-term holding.

  • Own the actual shares
  • Receive dividends and voting rights
  • Buy fractional shares starting at $1

BIIB Tokenized Stocks

Get BIIB price exposure through a blockchain-based token.


Suitable for trading outside U.S. market hours.

  • Token tracks the BIIB price
  • Trade 24/7
  • Trade on weekends and holidays

BIIB Stock Futures

Trade BIIB price movements with futures contracts.


Suitable for short-term positions.

  • Go long or short
  • Trade 24/7
  • Up to 20x leverage

How to Buy Biogen Inc. (BIIB) Stock on MEXC

Eligible investors can buy real shares of Biogen Inc. (BIIB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.

Step 1: Open and Verify Your RealStocks Account
Step 1: Open and Verify Your RealStocks Account
Log in to the MEXC App, go to Trade → RealStocks, and select Open Account. Complete the required account-opening and identity verification process with MEXC's partner licensed broker.
Step 2: Transfer USDT to Your RealStocks Account
Step 2: Transfer USDT to Your RealStocks Account
Go to Wallets → RealStocks and transfer USDT from your Spot Account to your RealStocks Account. RealStocks are quoted in USD, while account funding can be completed using USDT.
Step 3: Search for BIIB and Place Your Order
Step 3: Search for BIIB and Place Your Order
Open the RealStocks trading page and search for BIIB. Select a market or limit order, enter the price and quantity as required, review the order details, and submit your order. Once filled, the corresponding real shares will be held in your RealStocks Account.

Frequently Asked Questions (FAQ)

1.What is Biogen Inc. (BIIB) stock price today?
Biogen Inc. (BIIB) is currently trading at $251.37, up 0.25% ($0.63) from the previous close of $250.79. Intraday prices update in real time during regular trading hours.
2.Is BIIB stock going up or down today?
As of 2026-11-19 00:58:00, BIIB is trading at $251.37, up 0.25% ($0.63) from its previous close of $250.79. The stock has traded between $245.65 and $254.29 during today’s regular session. Past price movements do not guarantee future results.
3.What is BIIB pre-market price?
As of 2026-11-19 00:58:00, BIIB is trading at $246.02 in pre-market trading, down 1.90% ($4.77) from the previous close of $250.79. Pre-market prices reflect trading activity before the regular session opens and may experience lower liquidity and higher volatility.
4.What is BIIB after-hours price?
As of 2026-11-19 00:58:00, BIIB is trading at $250.58 in after-hours trading, down 0.31% ($0.78) from the regular-session close of $251.37. After-hours prices may differ from the regular session’s opening price due to lower liquidity and wider bid-ask spreads.
5.Is BIIB stock trading now?
BIIB trades on the NASDAQ exchange during regular hours, Monday through Friday, 9:30 AM to 4:00 PM ET, excluding public holidays. Pre-market and after-hours trading are also available through select brokers outside these hours.
6.Where does BIIB sit relative to its 52-week high and low?
Over the past 52 weeks, BIIB has traded between a low of $160.36 and a high of $261.00. At $251.37, the stock is positioned 90.4% of the way from its 52-week low to its 52-week high, providing context for its current price within the one-year trading range.
7.What sector is Biogen Inc. in?
Biogen Inc. (BIIB) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector. Sector classification helps investors compare it with companies exposed to similar market trends and competitive conditions.
8.What is Biogen Inc.'s market capitalization and where is it listed?
Biogen Inc. is listed on the NASDAQ exchange with a market capitalization of $37.20B. Market cap reflects the total market value of all outstanding shares and is commonly used to classify stocks by size.
9.How is BIIB valued in terms of P/E ratio and EPS?
BIIB trades at a P/E ratio of 106.68, based on trailing-twelve-month EPS of $2.35. P/E ratio compares the stock price to earnings per share and is a common starting point for assessing valuation relative to peers.
10.Does Biogen Inc. pay a dividend?
Biogen Inc. pays an indicated annual cash dividend of $0.00 per share, with a current dividend yield of 0.00% based on the latest share price. Dividend policies are subject to change at the board's discretion.

Explore More US Stocks

Largest Market Cap

See US stocks with the highest market capitalization

Most Actively Traded

Discover today's most actively traded US stocks

Top 5 Cryptocurrencies

Explore the cryptocurrencies with the highest market capitalization

Compliance Disclosure and Data Source

Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to BIIB, including Stocks, Tokenized Stocks, and Stock Futures.

Disclaimer

The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.

Search Stocks

BIIB Stock Calculator

Estimate the value between BIIB shares and USD.

BIIB Shares to USD

BIIB Shares
BIIB
BIIB
USD
USD
USD

1.00 BIIB shares = 251.366 USD

Calculations are estimates based on the latest available price and are for reference only.